Development Center for Biotechnology
The Development Center for Biotechnology (DCB) is Taiwan's pioneering biotech research organization established in 1984, dedicated to advancing biotechnological research, drug development, and industry collaboration. With a mission to improve quality of life, DCB focuses on innovative research, technology transfer, and fostering industry-academic partnerships to promote the growth of Taiwan's biotech sector.
Industries
Nr. of Employees
large (251-1000)
Development Center for Biotechnology
No. 1, Industry Innovation Building, No. 10, Sec. 2, Nangang Rd., Nangang District, Taipei City, Taiwan
Patents
Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof
US-11998613-B2
View DetailsHeterocycle compounds as Tyro3, Axl and MerTK (TAM) family of receptor tyrosine kinase inhibitors
US-11407757-B2
View Details
Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof
US-11998613-B2
View DetailsHeterocycle compounds as Tyro3, Axl and MerTK (TAM) family of receptor tyrosine kinase inhibitors
US-11407757-B2
View DetailsProducts
CHO-based high-yield expression system (CHO-C)
A CHO host and expression system comprising host cells, proprietary vectors and culture components designed for high-yield recombinant protein expression; available via licensing or contract development.
Bispecific antibody technology platform
A platform for designing and producing bispecific antibody formats optimized for stability, yield and dual-function mechanisms such as T‑cell engagement.
LNP nucleic acid formulation platform
Formulation capabilities and analytical workflows for lipid nanoparticle delivery of nucleic acid therapeutics, including particle manufacture and characterization.
CHO-based high-yield expression system (CHO-C)
A CHO host and expression system comprising host cells, proprietary vectors and culture components designed for high-yield recombinant protein expression; available via licensing or contract development.
Bispecific antibody technology platform
A platform for designing and producing bispecific antibody formats optimized for stability, yield and dual-function mechanisms such as T‑cell engagement.
LNP nucleic acid formulation platform
Formulation capabilities and analytical workflows for lipid nanoparticle delivery of nucleic acid therapeutics, including particle manufacture and characterization.
Services
End-to-end support for biologic drug discovery and development including antibody screening, optimization, characterization, and early process development.
Research support for chemical drug discovery and preclinical development activities.
Project integration services that combine discovery, development, regulatory support and commercialization planning to accelerate product translation.
Formulation development and testing services for lipid-nanoparticle based nucleic acid therapeutics including particle characterization and performance assays.
GLP-audited laboratory testing for preclinical studies and clinical sample analysis, including biosafety assessments.
Pilot-scale cGMP manufacturing capacity and facilitation of investment and commercialization for pilot plant operations producing clinical trial materials.
End-to-end support for biologic drug discovery and development including antibody screening, optimization, characterization, and early process development.
Research support for chemical drug discovery and preclinical development activities.
Project integration services that combine discovery, development, regulatory support and commercialization planning to accelerate product translation.
Formulation development and testing services for lipid-nanoparticle based nucleic acid therapeutics including particle characterization and performance assays.
GLP-audited laboratory testing for preclinical studies and clinical sample analysis, including biosafety assessments.
Pilot-scale cGMP manufacturing capacity and facilitation of investment and commercialization for pilot plant operations producing clinical trial materials.
Expertise Areas
- Protein biologics development
- Antibody engineering and bispecific antibodies
- Mammalian cell line and expression system development
- Preclinical testing and GLP bioassays
Key Technologies
- Bispecific antibody engineering
- CHO cell line development
- High‑yield mammalian expression systems
- Upstream/downstream process development for biologics
News & Updates
DCB and Sanwa Co-host Joint Medical Technology and Innovation Event
A collaborative event focusing on medical technology innovation and industry-academia partnerships, held at Taipei Nangang Exhibition Center.
Taiwan's Biotech Industry 40th Anniversary Video
A commemorative video celebrating 40 years of biotech development in Taiwan, highlighting achievements and future prospects.
Taiwan's Biotech Industry 40th Anniversary Conference
A conference marking the 40th anniversary of Taiwan's biotech industry, featuring industry leaders and policy discussions.
DCB's 40th Anniversary Video Review and Outlook
A retrospective and future outlook video for DCB's 40 years of biotech innovation.
Taiwan's Biotech Industry 40th Anniversary Event
Celebration event with industry stakeholders, showcasing Taiwan's biotech milestones.
DCB's development of a next-generation bispecific antibody platform has created new industry opportunities, with applications in cancer therapy.
DCB and Sanwa Co-host Joint Medical Technology and Innovation Event
A collaborative event focusing on medical technology innovation and industry-academia partnerships, held at Taipei Nangang Exhibition Center.
Taiwan's Biotech Industry 40th Anniversary Video
A commemorative video celebrating 40 years of biotech development in Taiwan, highlighting achievements and future prospects.
Taiwan's Biotech Industry 40th Anniversary Conference
A conference marking the 40th anniversary of Taiwan's biotech industry, featuring industry leaders and policy discussions.
DCB's 40th Anniversary Video Review and Outlook
A retrospective and future outlook video for DCB's 40 years of biotech innovation.
Taiwan's Biotech Industry 40th Anniversary Event
Celebration event with industry stakeholders, showcasing Taiwan's biotech milestones.
DCB's development of a next-generation bispecific antibody platform has created new industry opportunities, with applications in cancer therapy.